Human DC-SIGN+DC-SIGNR Alexa Fluor® 647-conjugated Antibody Summary
Extracellular domain
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
Background: DC-SIGN+DC-SIGNR
DC-SIGN (Dendritic Cell- Specific ICAM-3 Grabbing Non-Integrin) has been shown to play an important role in regulating dendritic cell (DC) and T cell interactions, including antigen presentation to T cells and enhancement of transinfection of CD4+ T cells by HIV-1 (1, 2). Efforts to identify additional type II membrane proteins resulted in the isolation of a molecule related in sequence to DC-SIGN known as DC-SIGNR (DC-SIGN Related) (3, 4). DC-SIGNR shares 73 - 80% amino acid homology with DC-SIGN and is located on human chromosome 19p13.3. Its structure is similar to DC-SIGN and therefore binds mannose residues in a calcium dependent fashion, including ICAM-3 and HIV-1 gp120 (5). DC-SIGNR, also known as L-SIGN (Liver/Lymph node-Specific ICAM-3-Grabbing Non-integrin) and DC‑SIGNR, is polymorphic since allelic variations of the exon 4 encoded sequence have been isolated (5). This is further supported by a study demonstrating the ability to isolate a large repertoire of DC-SIGNR transcripts largely the result of alternative splicing of the 7 coding exons (6). L-SIGN/DC-SIGNR is primarily transcribed in the liver and lymph nodes but not in monocyte derived DC (5). Expression of L-SIGN/DC-SIGNR is restricted to endothelial cells derived from liver sinusoids, lymph nodes sinuses and capillaries (7) although variable expression in placenta and some monocytic cell lines has also been reported, including both membrane and soluble isoforms of the protein (6). Expression of DC-SIGN is induced during the in-vitro generation of DC from either monocytes or bone marrow progenitors, with maximal surface expression at day 7 of culture (1). Immature DC in the skin and mature DC in the tonsil have been demonstrated to express DC‑SIGN (8). Analysis of various tissues and cell lines suggests that DC-SIGN expression is restricted to DC (1) although a more recent report finds evidence of expression in placenta, resting monocytes and monocytic cell lines (6). This discrepancy may be partially related to the multiple isoforms of DC-SIGN transcripts, including both membrane and soluble forms, as well as exon splice variants reported in the latter study (6). A detailed description of the additional properties of this monoclonal antibody may be found in references 9 and 10.
- Geijtenbeek, T.B.H. et al. (2000) Cell 100:575.
- Geijtenbeek, T.B.H. et al. (2000) Cell 100:587.
- Yokoyama-Kobayashi, M.T. et al. (1999) Gene 228:161.
- Soilleux, E.J. et al. (2000) J. Immunol. 165:2937.
- Bashirova, A.A. et al. (2001) J. Exp. Med. 193:671.
- Mummidi, S. et al. (2001) J. Biol. Chem., 2001 May 3 [epub ahead of print].
- Pohlman, S. et al. (2001) Proc. Natl. Acad. Sci. USA 98:2670.
- Geijtenbeek, T.B.H. et al. (2000) Nature Immunol. 1:353.
- Wu, L. et al. (2002) J. Virol. 76:5905.
- Baribaud, F. et al. (2002) J. Virol. 76:9135.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human DC-SIGN+DC-SIGNR Alexa Fluor® 647-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human DC-SIGN+DC-SIGNR Alexa Fluor® 647-conjugated Antibody and earn rewards!
Have you used Human DC-SIGN+DC-SIGNR Alexa Fluor® 647-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image